1. Home
  2. IGI vs SCLX Comparison

IGI vs SCLX Comparison

Compare IGI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Defined Opportunity Trust Inc.

IGI

Western Asset Investment Grade Defined Opportunity Trust Inc.

HOLD

Current Price

$16.66

Market Cap

98.8M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$8.13

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGI
SCLX
Founded
2009
2011
Country
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.8M
90.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IGI
SCLX
Price
$16.66
$8.13
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
33.9K
67.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.13
$3.60
52 Week High
$17.79
$34.27

Technical Indicators

Market Signals
Indicator
IGI
SCLX
Relative Strength Index (RSI) 61.67 31.85
Support Level $16.51 $8.12
Resistance Level $16.68 $9.50
Average True Range (ATR) 0.13 0.89
MACD 0.01 0.13
Stochastic Oscillator 60.10 7.91

Price Performance

Historical Comparison
IGI
SCLX

About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.

Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: